Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2023
October 2023, Vol 14, No 5
October 2023, Vol 14, No 5
Generic and Biosimilar Drugs Generate $408 Billion in Savings for America’s Patients and Healthcare System in 2022
Biosimilars
October 2023, Vol 14, No 5
Washington, DC—On September 6, 2023, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2023
U.S. Generic & Biosimilar Medicines Savings Report
highlighting the value of generic and biosimilar medicines.
Read More
Crystal S. Denlinger, MD, FACP, Named New CEO of NCCN
Healthcare Administration
October 2023, Vol 14, No 5
Crystal S. Denlinger, MD, FACP, has been named the new Chief Executive Officer (CEO) of the National Comprehensive Cancer Network.
Read More
“What’s in It for Me?” Helping Patients Understand Oncology Clinical Trials
By
Meg Barbor, MPH
2023 AONN+ Midyear Conference
October 2023, Vol 14, No 5
Cancer clinical trials offer patients an opportunity to be treated with the most cutting-edge and promising therapies available, but the majority of patients who are offered these trials still are not signing up for them.
Read More
Defining New Roles: What’s an Oncology Clinical Trial Nurse Navigator?
By
Meg Barbor, MPH
2023 AONN+ Midyear Conference
October 2023, Vol 14, No 5
To better assist their oncology patients with getting into clinical trials, providers at the University of Florida Health Cancer Center, Gainesville, recently decided that they needed a new kind of navigator: an oncology clinical trial nurse navigator.
Read More
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
FDA Approvals, News & Updates
October 2023, Vol 14, No 5
On
August 14, 2023
, the FDA approved melphalan hydrochloride for injection/Hepatic Delivery System (HDS; Hepzato Kit; Delcath Systems) as a liver-directed treatment for use in adults with uveal melanoma and unresectable hepatic metastases affecting <50% of the liver and no extrahepatic disease, or extrahepatic disease that is limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Read More
FDA Grants Accelerated Approval to Elrexfio for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & Updates
,
Multiple Myeloma
October 2023, Vol 14, No 5
On
August 14, 2023
, the FDA accelerated the approval of elranatamab-bcmm (Elrexfio; Pfizer), a bispecific B-cell maturation antigen–directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
Read More
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & Updates
,
Multiple Myeloma
October 2023, Vol 14, No 5
On
August 9, 2023
, the FDA accelerated the approval of talquetamab-tgvs (Talvey; Janssen Biotech), a bispecific GPRC5D-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
Read More
FDA Accelerates Approval of Akeega, the First Dual-Action Tablet for BRCA-Mutated Metastatic Prostate Cancer
FDA Approvals, News & Updates
,
Prostate Cancer
October 2023, Vol 14, No 5
On
August 11, 2023
, the FDA accelerated the approval of the fixed-dose combination of niraparib and abiraterone acetate (Akeega; Janssen Biotech), with prednisone, for the treatment of adults with deleterious or suspected deleterious
BRCA
-mutated, castration-resistant prostate cancer, as determined by an FDA-approved test. The FDA granted this approval priority review.
Read More
Gavreto Receives Regular Approval for Patients With RET-Positive NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
October 2023, Vol 14, No 5
On
August 9, 2023
, the FDA granted regular approval to pralsetinib (Gavreto; Genentech), a kinase inhibitor of wild-type
RET
and oncogenic
RET
fusions and mutations, for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) and
RET
fusion–positive gene mutation, as detected by an FDA-approved test.
Read More
Zanidatamab Demonstrates Efficacy in Refractory HER2-Amplified Biliary Tract Cancer
Emerging Therapies
,
ASCO 2023 Highlights
October 2023, Vol 14, No 5
Improving clinical outcomes in the second line of treatment in patients with advanced biliary tract cancer remains an important goal, and researchers have been exploring various therapeutic targets, including
HER2
, an oncogene that creates a protein that encourages cell growth and accelerates the spread of cancers.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma